NASDAQ
INSM
Last Price
US $126.33
Valuation
Financial
Performance
Cash flow to debt coverage
Insmed Incorporated cash flow to debt ratio of -121.72% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Insmed Incorporated's free cash flow has decreased 37.09% from $-705.80M last year to $-967.58M, signaling decreasing performance
Debt-to-equity ratio
Insmed Incorporated's debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
Insmed Incorporated's debt has decreased relative to shareholder equity from 4.60 last year to 0.05 today, signaling strengthened financials
Net debt to EBITDA
Insmed Incorporated has a net cash position, so leverage is healthy.
Interest coverage
Insmed Incorporated's interest coverage ratio is -10.05, which means that the company struggles to meet interest obligations, signaling financial risk.
Profit margin growth
Insmed Incorporated's profit margin has increased (-69.38%) in the last year from -251.24% to -76.94%, signaling increasing performance
Current ratio
Insmed Incorporated's short-term assets of $1.79B exceed its short-term liabilities of $468.87M
Return on assets
Insmed Incorporated's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Insmed Incorporated's return on equity of -111.26%, is lower than 15.00%, indicating bad performance
Earnings quality
Insmed Incorporated's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Insmed Incorporated had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
Insmed Incorporated has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Insmed Incorporated has negative free cash flow, indicating cash burn
Earnings growth
Insmed Incorporated's yearly earnings has decreased 39.73% since last year from $-913.77M to $-1.28B, signaling decreasing performance
Revenue growth
Insmed Incorporated's yearly revenue has increased 66.73% since last year from $363.71M to $606.42M, signaling increasing performance
Return on invested capital
ROIC -48.85% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Insmed Incorporated's 3-year revenue CAGR of 35.20% is positive, indicating growing revenue over the past 3 years
Revenue consistency
Insmed Incorporated had revenue growth in 5 out of 5 years, indicating consistent revenue performance
Return on equity consistency
Insmed Incorporated had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
Insmed Incorporated has insufficient data to evaluate this check.
Earnings yield (TTM)
Insmed Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
Insmed Incorporated is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Insmed Incorporated has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Insmed Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Insmed Incorporated has a price-to-book ratio of 38.66x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Price-to-sales ratio (TTM)
Insmed Incorporated has a price-to-sales ratio of 25.74x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-111.26%
Return on equity
ROIC: -48.85%
Valuation History
-
Price to Earnings
EV/EBITDA: -35.6X
Cash flow
Profit margin
-26.55%
Cash flow
-25.23%
Fair Value
Market $126.33
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.